On May 1, the clinical study of the inactivated vaccine of the New Coronavirus variant developed by Sinopharm China Biological Institute of Beijing Biological Products was officially launched in Hangzhou, and the first dose of vaccination was completed on the same day.
This is the world's first inactivated covid-19 vaccine to enter clinical trials against the Ami kerong variant.
Li Lanjuan, an academician of the Chinese Academy of Engineering, said in an interview that the current Opmi kerong virus still seriously threatens the health of personnel, and the research and development of related vaccines is of great significance.
Image source: China News Network
Li Lanjuan said: "The development of the vaccine of the variant strain of Omicron is very important, of course, the original vaccine is still effective, but after the development of the vaccine for the mutant strain, it may have a better immune effect." This also proves the speed of China's anti-epidemic work and China's efficiency. We believe that through rigorous clinical research, the safety and efficacy of the vaccine are further demonstrated to ensure the application of future vaccines. ”
The new vaccine that has entered the clinical research stage, how the clinical effect is, and whether those who have been vaccinated with the new crown vaccine can continue to be vaccinated, Li Lanjuan said that it is necessary to further explore and verify the clinical response in stages.
Image source: China News Network
Li Lanjuan stressed that of course, people who have not been vaccinated can get a new vaccine, and the next step is to do clinical trials for people who have been vaccinated to verify whether it will be more effective. At the same time, further observations of the clinical response to the new vaccine are also observed to prove the safety of the new vaccine.
The vaccine research and development of the Aomi Kerong variant was launched on December 9, 2021, and was approved by the State Food and Drug Administration for clinical trials on April 26, 2022. The first 200 participants are planned to be recruited and will be carried out in people aged 18 years and older. After passing the screening, volunteers are required to receive 2 doses, and the safety and immunogenicity of the Olympian vaccine will be evaluated in people aged 18 years and over who have not been vaccinated against the new crown virus vaccine. There is no need to be hospitalized during the study period, and the researchers confirm that there are no abnormalities before leaving the research center.
Comprehensive 丨China News Network, Hangzhou Network
Typography 丨 Zhang Jing